Trial Profile

A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine Carcinoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surufatinib (Primary) ; Toripalimab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Neuroendocrine carcinoma
Focus Registrational; Therapeutic Use
Acronyms SURTORI-01
Sponsors Hutchison MediPharma; HUTCHMED

11 Dec 2023 Planned End Date changed from 30 Nov 2023 to 31 May 2025.
11 Dec 2023 Planned primary completion date changed from 31 Jul 2023 to 31 May 2025.
18 Sep 2021 According to a HUTCHMED media release, the first patient was dosed in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com